
Parnax Lab Ltd is Rated Strong Sell
2026-11-19 10:10:43Parnax Lab Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 07 September 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 19 November 2026, providing investors with the latest perspective on the company’s position.
Read More
Parnax Lab Ltd Valuation Shifts to Very Attractive Amid Mixed Returns
2026-11-16 08:00:22Parnax Lab Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from an attractive to a very attractive rating. Despite recent price pressures and a mixed performance relative to the Sensex, the stock’s improved price-to-earnings and price-to-book ratios suggest a potential revaluation opportunity for investors willing to navigate its risk profile.
Read More
Parnax Lab Ltd is Rated Strong Sell
2026-10-31 10:10:13Parnax Lab Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 07 September 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 31 October 2026, providing investors with the most recent and relevant data to assess the company’s outlook.
Read More
Parnax Lab Ltd is Rated Strong Sell
2026-10-05 10:10:19Parnax Lab Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 07 September 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 05 October 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.
Read More
Parnax Lab Ltd is Rated Strong Sell
2026-09-24 10:10:27Parnax Lab Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 07 September 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 September 2026, providing investors with the most up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read More
Parnax Lab Ltd Forms Death Cross, Signalling Potential Bearish Trend
2026-09-21 18:00:13Parnax Lab Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has recently formed a Death Cross, a technical pattern where the 50-day moving average crosses below the 200-day moving average. This development signals a potential shift towards a bearish trend, reflecting deteriorating momentum and raising concerns about the stock’s near- to medium-term outlook.
Read MoreParnax Lab Ltd Falls 2.90%: Downgrade and Lower Circuit Trigger Define Week
2026-09-12 17:03:54Key Events This Week 7 Sep: Downgrade to Strong Sell announced 8 Sep: Stock drops 3.63% following downgrade 10 Sep: Hits lower circuit amid heavy selling pressure 11 Sep: Week closes at Rs.127.05, down 2.90% Week OpenRs.130.85 Week CloseRs.127.05-2.90%</d...
Read More
Parnax Lab Ltd Locks at Lower Circuit With 20% Loss — Sellers Queue, No Buyers in Sight
2026-09-10 10:00:12At Rs 104.00, sellers were still queuing — but there were no buyers willing to take the other side. Parnax Lab Ltd locked at its lower circuit of 20% on 09 Sep 2026, with unfilled sell orders and a frozen price, signalling a severe imbalance in supply and demand.
Read More
Parnax Lab Ltd is Rated Strong Sell
2026-09-01 10:10:57Parnax Lab Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 17 August 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 01 September 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and technical outlook.
Read MoreBoard Meeting Intimation for Consideration And Approval Of Financial Results Along With Limited Review Report For The Quarter (Q2) And Half Year Ended 30Th September 2026.
03-Nov-2026 | Source : BSEParnax Lab Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2026 inter alia to consider and approve Standalone and Consolidated Un-audited IND- AS Compliant Financial Results along with Limited Review Report for the quarter (Q2) and half year ended 30th September 2026 pursuant to Regulation 33 of Listing Obligation and Disclosure Requirement 2015.
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
14-Oct-2026 | Source : BSEPlease find enclosed herewith the confirmation certificate from RTA under Reg. 74 (5) of SEBI (DP) Regulations 2018.
Shareholder Meeting / Postal Ballot-Scrutinizers Report
30-Sep-2026 | Source : BSEPlease find enclosed herewith the Voting results of AGM held on 29.09.2026
Corporate Actions
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available